David Southwell

We've also been testing our drug against the toxic warheads of many of the leading ADCs.

And ADCs and taxanes have a safety profile that is not that good.

ADCs can have vision loss and some other things.

And what if you can lower the dose of taxanes or lower the dose of an ADC and by adding our drug, which has a relatively much cleaner safety profile, you could just create a better therapeutic index for the patient.

And that's, so we really have two different approaches.

One is a monotherapy approach and the other is a combination approach.

We're starting combination studies in March and our plan is to

We're starting it with taxis, but our plan is to really roll that out.

So we'll be doing monotherapy studies, pan cancer, and we'll be doing combination studies to get us from third line therapy into first line therapy.

Really hard to displace first line therapy.

As you can imagine, if you're an oncologist, someone comes along and says, oh, we've got this great new drug.

You know, we think you should use it in first line therapy.

The oncologist is going to say, look, I've been using, you know, carboplatin and taxanes for decades, and I've got very sick patients that are coming in.

There's no way you're going to replace that.

But if we can offer them something they can add to it that's going to perhaps enable them to lower the dose or is going to increase the response rate of it, then they're much more open to that.

So that's kind of where we're going, and we're very busy with that.

The two discovery assets we have are also chromosomally, they also target chromosomally unstable cancers, but it's a different target than Kif-18A.

So we've done a lot of, we're really the leaders in research into chromosomal instability.

And financing wise, our goal is to do some licensing deals on the early preclinical assets and use that to fund, you know, the main event, which is our Kif-18A drug.

my previous company, we're not really an immunotherapy company.